Furthermore, Schedule III could mean that independent researchers—not just pharma shills—might finally get a seat at the table. Universities won’t have to fear losing their funding just for touching the plant. We might see a new wave of “less biased” research that explores the nuances of the entourage effect or minor cannabinoids like THCV or CBG, rather than just focusing on how much “reefer madness” can be induced in a lab rat.
This column originally appeared in Cultivated, a cannabis industry newsletter. Subscribe here. You know the…
The DEA has opened a new registration process for state-licensed medical cannabis manufacturers, distributors and…
This November gathering will bring psychedelic education into conversation with music, visual art, comedy, philosophy,…
Ten p.m. on a Glendale balcony, two floors above the theater that just screened the…
We analyzed seven different 2026 rankings to find the true top 10 cannabis strains in…
A land-rooted look at the growers reshaping cannabis through living soil, ecological intelligence and regenerative…